NovaTarg Therapeutics is a privately owned and operated pharmaceutical company that has established a cell-based screening platform to identify tissue selective AMPK activators.
This approach has led to the discovery of NT1195, a novel biguanide to treat type 2 diabetes (T2D) patients with impaired renal function.
No oral anti-diabetic drugs (OADs) have been designed specifically for T2D patients with kidney disease. In fact, virtually all OADs require dose adjustment and monitoring.
We have been awarded ~$6.5 million in Federal grant funding for projects on T2D, polycystic kidney disease (PKD) and cancer.
Intellectual property rights covering our drug candidates were filed in December 2016.